Home

Multiplicom establishes research collaborations with ICAN and ICM

    Focused on development of genetic tests in cardiovascular, metabolic and neurological diseases.
    Today Multiplicom, ICAN and ICM announced they signed an agreement to jointly develop a new generation of molecular diagnostic tests to identify disease predisposition mutations in cardiovascular, metabolic and neurological diseases. Multiplicom’s expertise in the development of massive parallel sequencing based molecular diagnostics in combination with the disease specific knowledge and the availability of well documented samples at ICAN and ICM will lead to the development of innovative diagnostic tests that will help patients and their doctors to prevent and/or cure disease in an early stage.
    Multiplicom is a Belgian diagnostics company, specialized in the design, development, production, and commercialization of innovative molecular genetic tests based on massive parallel sequencing. ICAN and ICM are two Hospital-University Institutes (IHU) at Hôpital Pitié Salpêtrière in Paris that are specialized in cardiovascular & metabolic and neurological diseases, respectively. Under the collaboration the parties will closely work together on a number of specific projects with the aim of developing and validating diagnostic tests for the identification of disease related mutations based on massive parallel sequencing. Multiplicom will be responsible for the commercialization of the resulting products. As a first project an early onset diabetes test will be developed, with additional projects following shortly thereafter.
    “I’m delighted by the collaboration as it will allow to translate our world class science into routine tests that can contribute to improve diagnosis in our patients” said Pr. Karine Clément from ICAN.
    “This collaboration joins together experts in academic research and industry to more rapidly advance research into routine clinical practice” added Bertrand Fontaine from IHU-A-ICM. “With this agreement Multiplicom demonstrates its commitment to partner with key opinion leaders in multiple disease areas to develop innovative products that meet real needs in the clinic” added Dirk Pollet, CEO of Multiplicom.
    The press release can be found here